BEAG vs ABUS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABUS Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Options & Structure while BEAG counters with relative strength in Momentum & Technical. Fundamentally, BEAG trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ABUS at 10.2x Forward P/E and 80.1% operating margin (-43.5% YoY). In options structure, BEAG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABUS sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BEAG | ABUS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $169.1M | $623.9M | Larger Scale | ABUS |
| Trailing P/E Ratio Valuation | 59.0x | 3.6x | Lower Multiple | ABUS |
| Forward P/E Ratio Valuation | N/M | 10.2x | Lower Multiple | ABUS |
| Revenue Growth (YoY) Growth | +0.0% | -43.5% | Higher Growth | BEAG |
| Operating Margin (TTM) Profitability | 0.0% | 80.1% | Higher Margin | ABUS |
| Net Profit Margin Profitability | 0.0% | 121.2% | Higher Margin | ABUS |
| Return on Equity (ROE) Capital Efficiency | 0.0% | 269.6% | Higher ROE | ABUS |
| 52-Week Range Position Momentum | 47% ($10โ$11) | 27% ($4โ$5) | Stronger Trend | BEAG |
| Beta / 30D Volatility Risk Regime | -0.01ฮฒ ยท 8% Vol | 1.04ฮฒ ยท 48% Vol | Lower Realized Risk | BEAG |
| Unified Institutional Score Composite Signal | 52.7 / 100 (HOLD) | 43.4 / 100 (HOLD) | Higher Composite | BEAG |